Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 25796459

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2015 May 9
First author
Moskowitz CH

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2015 May 9;385(9980):1810-2. doi: 10.1016/S0140-6736(15)60583-9.
    note
    Source null
    related pmid
    25796457
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2015 Jun;12(6):312. doi: 10.1038/nrclinonc.2015.69.
    note
    Source null
    related pmid
    25869463
    relationship
    Comment in
  3. citation
    Lancet. 2015 Aug 8;386(9993):532. doi: 10.1016/S0140-6736(15)61474-X.
    note
    Source null
    related pmid
    26293440
    relationship
    Erratum in
  4. citation
    Lancet. 2015 Aug 8;386(9993):532. doi: 10.1016/S0140-6736(15)61475-1.
    note
    Source null
    related pmid
    26293441
    relationship
    Erratum in

Authors and identifiers

  1. name
    Moskowitz CH
    type
    Author
  2. name
    Nademanee A
    type
    Author
  3. name
    Masszi T
    type
    Author
  4. name
    Agura E
    type
    Author
  5. name
    Holowiecki J
    type
    Author
  6. name
    Abidi MH
    type
    Author
  7. name
    Chen AI
    type
    Author
  8. name
    Stiff P
    type
    Author
  9. name
    Gianni AM
    type
    Author
  10. name
    Carella A
    type
    Author
  11. name
    Osmanov D
    type
    Author
  12. name
    Bachanova V
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Moskowitz CH
    type
    Author
  2. name
    Nademanee A
    type
    Author
  3. name
    Masszi T
    type
    Author
  4. name
    Agura E
    type
    Author
  5. name
    Holowiecki J
    type
    Author
  6. name
    Abidi MH
    type
    Author
  7. name
    Chen AI
    type
    Author
  8. name
    Stiff P
    type
    Author
  9. name
    Gianni AM
    type
    Author
  10. name
    Carella A
    type
    Author
  11. name
    Osmanov D
    type
    Author
  12. name
    Bachanova V
    type
    Author
bibliography ids
  1. nci-bib-7cd9092019b1afc2f715e887
book metadata
content sha256
f8f9b74b881c12ea9dec5d04cae050202373734bc3b128447671832103a77a50
document type
citation
dois
  1. 10.1016/S0140-6736(15)60165-9
electronic publication date
display
2015 Mar 19
precision
day
year
2015
evidence scope
bibliographic_metadata_only
id
pubmed:25796459
immutable id
pubmed:25796459@f8f9b74b881c12ea9dec5d04cae050202373734bc3b128447671832103a77a50
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
9980
name
Lancet (London, England)
nlm unique id
2985213R
pages
1853-62
volume
385
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2015 May 9;385(9980):1810-2. doi: 10.1016/S0140-6736(15)60583-9.
    note
    Source null
    related pmid
    25796457
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2015 Jun;12(6):312. doi: 10.1038/nrclinonc.2015.69.
    note
    Source null
    related pmid
    25869463
    relationship
    Comment in
  3. citation
    Lancet. 2015 Aug 8;386(9993):532. doi: 10.1016/S0140-6736(15)61474-X.
    note
    Source null
    related pmid
    26293440
    relationship
    Erratum in
  4. citation
    Lancet. 2015 Aug 8;386(9993):532. doi: 10.1016/S0140-6736(15)61475-1.
    note
    Source null
    related pmid
    26293441
    relationship
    Erratum in
outcomes validated
false
pmid
25796459
provenance
batch id
74265f1b641f04cf2d05
provider
NCBI PubMed ESummary
record sha256
b8a8146e79e2ee9a19896112af699f4ac53e048915de76331d59f2081632f7f0
response sha256
193df6bb6d2ac41af73dc445bf8171fe8076a8c8a5e98882a3d6a1ada428b0f0
retrieved at
2026-09-09T23:47:10.134322+00:00
publication date
display
2015 May 9
precision
day
year
2015
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/25796459/
title
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Preserved source evidence · Not medical advice